Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
ln Vitro |
In the labeled 6-10B cells, N,N'-Dinitrosopiperazine (0.5-100 μM; 48 hours) does not exhibit any inhibitory effects, and DNP treatment in the 0.5-8 μM concentration range does not significantly change LDH activity. But starting at 10 μM, it becomes cytotoxic[1]. 6-10B cell invasion and motility are induced in a dose-dependent manner by N,N'-Dinitrosopiperazine (2-8 μM; 24 hours). At 6 μM, DNP increases cell motility by 328.2% and increases cell invasion by 421.7 percent compared to the control group[1]. In CNE1 cells, phospho-LYRIC s568 and LYRIC expression are upregulated by 6 μM of N,N'-Dinitrosopiperazine over a 24-hour period[1].
|
---|---|
ln Vivo |
In vivo NPC metastasis is facilitated by N,N'-Dinitrosopiperazine (40 mg/kg; 30 days) injection into the tail veins, which decreases cell motility and invasion. Phospho-LYRIC expression is more prevalent in the metastatic tumors of DNP-treated mice compared to untreated control mice, according to an IHC result[1].
|
Cell Assay |
Cell Viability Assay[1]
Cell Types: The labeled 6-10B cells Tested Concentrations: 0.5, 1, 2, 4, 6, 8, 10, 20, 40, 80, or 100 μM Incubation Duration: 48 hrs (hours) Experimental Results: Had no inhibitory effects at the concentration 0-8 μM. Western Blot Analysis[1] Cell Types: The NPC cell line CNE1 Tested Concentrations: 6 μM Incubation Duration: 24 hrs (hours) Experimental Results: Increased phospho-LYRIC s568 and LYRIC expression. |
Animal Protocol |
Animal/Disease Models: BABL/c nude mice injected with labeled 6-10B cell suspensions (1 × 104 cells) with or without DNP(40 mg/kg)[1]
Doses: 40 mg/kg Route of Administration: Injected into the tail veins; 30 days Experimental Results: Induced LYRIC phosphorylation at serine 568 associated with NPC metastasis in vivo. |
References |
[1]. Damao Huang, et al. Identification of Novel Signaling Components in N,N'-dinitrosopiperazine-mediated Metastasis of Nasopharyngeal Carcinoma by Quantitative Phosphoproteomics. BMC Cancer. 2014 Apr 5;14:243.
|
Molecular Formula |
C4H8N4O2
|
---|---|
Molecular Weight |
144.13
|
CAS # |
140-79-4
|
Related CAS # |
N,N'-Dinitrosopiperazine-d8;69340-07-4
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
C1CN(CCN1N=O)N=O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 6.9382 mL | 34.6909 mL | 69.3818 mL | |
5 mM | 1.3876 mL | 6.9382 mL | 13.8764 mL | |
10 mM | 0.6938 mL | 3.4691 mL | 6.9382 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.